ARCT240517P25000
- 0.05
- 0.000.00%
Arcturus Therapeutics Newsroom
Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $58
Wells Fargo analyst Yanan Zhu maintains $Arcturus Therapeutics(ARCT.US)$ with a buy rating, and maintains the target price at $58.According to TipRanks data, the analyst has a success rate of 42.0% an
COVID-19 Vaccine Makers Rebound Amid Post-pandemic Prospects
Express News | Achilles Therapeutics And Arcturus Therapeutics Announce Research Collaboration To Explore MRNA Cancer Vaccines
Express News | Achilles Therapeutics Announces Research Collaboration With Arcturus Therapeutics to Explore Second-Generation Personalized Mrna Cancer Vaccines
CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine
Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior immunogeni
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and
Arcturus Therapeutics (NASDAQ:ARCT) Making Significant Strides Towards Growth
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $86
Arcturus Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 219.47% Canaccord Genuity $87 → $86 Maintains Buy 03/20/2024 122.88% HC Wainwright & Co. → $60
Buy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical Advancements
Earnings Call Summary | Arcturus Therapeutics(ARCT.US) Q1 2024 Earnings Conference
The following is a summary of the Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript:Financial Performance:Arcturus reported Q1 2024 revenues of $38 million, an increase from
Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech pioneer, unequivocally backed the mRNA technology, w
Arcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ...
Arcturus Therapeutics | 10-Q: Quarterly report
Arcturus Therapeutics: Cash Runway Remains Strong for at Least 3 Years Into 1Q of FY27
Arcturus Therapeutics: Cash Runway Remains Strong for at Least 3 Years Into 1Q of FY27
Arcturus Therapeutics: JP Morgan Engaged to Monetize Investment in ARCALIS JV in Japan >ARCT
Arcturus Therapeutics: JP Morgan Engaged to Monetize Investment in ARCALIS JV in Japan >ARCT
Arcturus Therapeutics: Commercial Manufacture of Kostaive on Track for Delivery of Initial 4 M Doses in 3Q
Arcturus Therapeutics: Commercial Manufacture of Kostaive on Track for Delivery of Initial 4 M Doses in 3Q